The four factor prognostic model for ibrutinib in chronic lymphocytic leukemia

The four factor prognostic model for ibrutinib assigns one point for each of the following variables:
Del(17p) or TP53 mutation
Serum beta-2 microglobulin ≥5 mg/L
Lactate dehydrogenase >250 units/L
Relapsed or refractory disease
The sum of these points determines the prognostic score, which separates patients into three risk groups with different estimated PFS and OS following treatment with single-agent ibrutinib:
Score	Risk group	3-year PFS (%)	3-year OS (%)
0 or 1 point	Low risk	87	93
2 points	Intermediate risk	74	83
3 or 4 points	High risk	47	63

Data from: Ahn IE, Tian X, Ipe D, et al. Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. J Clin Oncol 2021; 39:576.

Graphic 131543 Version 1.0

خرید پکیج

The four factor prognostic model for ibrutinib in chronic lymphocytic leukemia